263 results on '"Park, Junsik"'
Search Results
2. Globally shared TCR repertoires within the tumor-infiltrating lymphocytes of patients with metastatic gynecologic cancer
3. Durvalumab with or without tremelimumab plus chemotherapy in HRR non-mutated, platinum-resistant ovarian cancer (KGOG 3045): A phase II umbrella trial
4. OPERA: a phase II trial of oregovomab plus non-platinum chemotherapy in PARP inhibitor/platinum-resistant ovarian cancer.
5. What’s fairness?
6. Anti-4-1BB×PD-L1 Bispecific Antibody Reinvigorates Tumor-Specific Exhausted CD8+ T Cells and Enhances the Efficacy of Anti-PD-1 Blockade
7. Supplementary Figures S1-11 from CEACAM1 Marks Highly Suppressive Intratumoral Regulatory T Cells for Targeted Depletion Therapy
8. Supplementary Tables S1-7 from CEACAM1 Marks Highly Suppressive Intratumoral Regulatory T Cells for Targeted Depletion Therapy
9. Flash light sintered SDC cathodic interlayer for enhanced oxygen reduction reaction in LT-SOFCs
10. The efficacy of subsequent chemotherapy in ovarian cancer patients who progressed in prior PARPi
11. Promising immunotherapeutic strategies based on different immune characteristics of tumor-infiltrating lymphocytes according to molecular classification in endometrial cancer
12. Clinical significance of terminally exhausted CD8 T cells in malignant ascites in patients with epithelial ovarian cancer
13. PD-1 blockade improves treatment responses to PARP inhibitors by targeting PD-1+ regulatory T cells in patients with epithelial ovarian cancer
14. Final primary analysis in the original cohort of KGOG3046/TRU-D: a phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer
15. PD-1 expression level and BRCA1/2 mutations status determine anti-PD-1-induced reinvigoration of tumor-infiltrating CD8 T cells in advanced-stage epithelial ovarian cancer
16. Durvalumab with or without tremelimumab plus chemotherapy in HRR non-mutated, platinum-resistant ovarian cancer (KGOG 3045): a phase II umbrella trial
17. Oregovomab and non-platinum chemotherapy in PARP inhibitor-resistant ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: a multicenter, two-cohort, single-arm phase 2 trial (OPERA/KGOG 3065/APGOT-OV6)
18. Design of a Wideband Coupled Feed Dipole Antenna for PCL Array Systems
19. PR061/#869 A retrospective study on the comparison of responsiveness of each chemotherapy for recurrent ovarian cancer after maintenance treatment with PARP inhibitors
20. EP015/#747 Prognostic impact of CD73 expression in epithelial ovarian cancer
21. EP264/#775 Genomic alteration before and after progression on first exposure to parp inhibitor (PARPi) among ovarian cancer patients
22. PR003/#357 Peripheral PD-1+regulatory T cells for predicting treatment response to parp inhibitor maintenance in patients with epithelial ovarian cancer
23. Phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer: primary analysis in the original cohort of KGOG3046/TRU-D
24. Comprehensive genomic and immunohistochemical profiles and outcomes of immunotherapy in patients with recurrent or advanced cervical cancer
25. Supplementary Figures S1-11 from CEACAM1 Marks Highly Suppressive Intratumoral Regulatory T Cells for Targeted Depletion Therapy
26. Data from CEACAM1 Marks Highly Suppressive Intratumoral Regulatory T Cells for Targeted Depletion Therapy
27. Supplementary Tables S1-7 from CEACAM1 Marks Highly Suppressive Intratumoral Regulatory T Cells for Targeted Depletion Therapy
28. Abstract 6424: Immune characteristics and anti-PD-1-induced reinvigoration capacity of tumor-infiltrating lymphocytes in ovarian clear cell carcinoma relative to high-grade serous ovarian carcinoma
29. Abstract 4615: Differential immune characteristics and anti-PD-1-induced reinvigoration capacity of tumor-infiltrating lymphocytes according to ProMisE classifier in endometrial cancer
30. Supplementary Table S2 from PD-1 Blockade Reinvigorates Bone Marrow CD8+ T Cells from Patients with Multiple Myeloma in the Presence of TGFβ Inhibitors
31. Supplementary Data from PD-1 Blockade Reinvigorates Bone Marrow CD8+ T Cells from Patients with Multiple Myeloma in the Presence of TGFβ Inhibitors
32. Supplementary Figures S1-S21 from PD-1 Blockade Reinvigorates Bone Marrow CD8+ T Cells from Patients with Multiple Myeloma in the Presence of TGFβ Inhibitors
33. Programmed cell death ligand 1 alleviates psoriatic inflammation by suppressing IL-17A production from programmed cell death 1–high T cells
34. Promising immunotherapeutic strategies based on different immune characteristics of tumor-infiltrating lymphocytes according to ProMisE classifier in endometrial cancer (028)
35. Frequency of peripheral PD-1+regulatory T cells is associated with treatment responses to PARP inhibitor maintenance in patients with epithelial ovarian cancer.
36. CEACAM1 marks highly suppressive intratumoral regulatory T cells for targeted depletion therapy
37. Sensitivity to PARP inhibitor lead to response to subsequent therapy in ovarian cancer
38. Laparoscopic interval debulking surgery following neoadjuvant chemotherapy similar oncologic outcomes to laparotomy for advanced ovarian cancer
39. A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in patients with platinum-sensitive, recurrent ovarian cancer previously treated with a PARP inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)/NIRVANA-R trial
40. Human epidermal growth factor receptor-2 (HER2) receptor expression and its dynamic change in patients with ovarian cancer
41. Dynamic immunological changes on tumor microenvironment during treatment in cervical cancer
42. The feasibility and safety of interval debulking surgery in patients with advanced ovarian cancer receiving neoadjuvant chemotherapy with tremelimumab and durvalumab
43. Differential immune characteristics and anti-PD-1-induced reinvigoration capacity of tumor-infiltrating lymphocytes according to ProMisE classifier in endometrial cancer
44. Immunological characteristics of malignant ascites in newly diagnosed or recurrent epithelial ovarian cancer
45. Potential therapeutic roles of PD-1 blockade in reinvigorating tumor-infiltrating CD8 T cells in patients with BRCA1/2 mutated ovarian cancer
46. Immune characteristics of tumor-infiltrating lymphocytes in endometrial cancer; molecular classification
47. Oregovomab and non-platinum chemotherapy in PARP inhibitor resistant ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: a multicenter, two-cohort, single-arm phase 2 trial (OPERA/KGOG 3065/APGOT-OV6)
48. Circulating tumor DNA as a predictive and prognostic biomarker for BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer receiving triplet maintenance therapy (OPEB-01)
49. Differential implication of PET-CT response and pathologic complete response (pCR) in ovarian cancer patients undergoing neoadjuvant chemotherapy (NAC) with or without immunotherapy
50. Final primary analysis in the original cohort of KGOG3046/TRU-D: a phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.